NCT07304154 2026-04-21
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
Gilead Sciences
Phase 1 Recruiting
Gilead Sciences
Tongji Hospital
Kyverna Therapeutics
Arcellx, Inc.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company